Pesavento Matthew, Loibl Cäzilia, Moulton Stephanie, Haurin Donald, Hyer Madison, Dalmacy Djhenne, Joseph Joshua J
The Ohio State University, Columbus.
JAMA Netw Open. 2025 Jul 1;8(7):e2523453. doi: 10.1001/jamanetworkopen.2025.23453.
Type 2 diabetes is common and associated with negative financial health.
To investigate the association of type 2 diabetes with adverse financial outcomes and identify patient groups at risk.
DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation study analyzed electronic health records linked to credit records of adults aged 18 years or older with at least 1 medical encounter at a primary care medical center in Ohio from October 1, 2017, to December 31, 2021. Patient health records were included if they reported a glycated hemoglobin value, diagnostic code for type 2 diabetes, or a prescription for antidiabetic medications.
Type 2 diabetes.
The main outcome was adjusted probability of any adverse financial outcomes, below-prime credit score, nonmedical and medical debt in collections, delinquent debt, debt charge-offs, bankruptcy filing, and foreclosure. Adjustments included age, sex, race, Hispanic ethnicity, wage earnings, health insurance type, exposure period, and quarter-year indicators.
The study population included 166 285 patients (mean [SD] age, 52.3 [15.3] years; 55.0% female; 0.2% of American Indian or Alaska Native or Native Hawaiian or Pacific Islander, 3.5% Asian, 19.1% Black, and 73.2% White race; 0.8% identifying as multiracial; 2.1% of Hispanic and 97.9% of non-Hispanic ethnicity), of whom 41.7% were diagnosed with type 2 diabetes. In the analytic sample, 50.8% lacked earned income, and 32.6% had Medicare coverage. For patients with vs without diabetes, estimated probabilities were significantly higher for any adverse financial outcomes (64.5% [95% CI, 64.1%-64.9%] vs 49.9% [95% CI, 49.6%-50.2%]), below-prime credit score (59.7% [95% CI, 59.3%-60.1%] vs 45.9% [95% CI, 45.6%-46.2%]), medical collections (36.9% [95% CI, 36.5%-37.3%] vs 23.9% [95% CI, 23.7%-24.2%]), nonmedical collections (38.4% [95% CI, 38.0%-38.8%] vs 27.7% [95% CI, 27.5%-28.0%]), delinquent debt (23.3% [95% CI, 22.9%-23.7%] vs 15.6% [95% CI, 15.4%-15.8%]), debt charge-offs (15.4% [95% CI, 15.1%-15.8%] vs 10.1% [95% CI, 9.9%-10.2%]), bankruptcy filings (2.1% [95% CI, 2.0%-2.3%] vs 1.4% [95% CI, 1.3%-1.5%]), and foreclosures (0.5% [95% CI, 0.5%-0.6%] vs 0.3% [95% CI, 0.2%-0.4%]). Patients with diabetes experienced more adverse financial outcomes (1.9 vs 1.2) and had lower credit scores (mean [SE], 618.7 [0.4] vs 664.2 [0.5]) than those without diabetes. For patients with vs without diabetes, the maximum amount of nonmedical debt in collection was higher ($1875 [95% CI, $1834-$1916] vs $1361 [95% CI, $1333-$1389]), as was delinquent debt ($11 387 [95% CI, $10 796-$11 977] vs $7630 [95% CI, $7305-$7955]). The adjusted prevalence of adverse financial outcomes was higher among patients of Black race, enrolled in Medicaid, of Hispanic ethnicity, younger than 65 years, without earned income, and of female sex.
This economic evaluation of patient health records linked to credit records and wage earnings shows a positive association of type 2 diabetes with adverse financial outcomes. These findings suggest that patients with type 2 diabetes may experience substantially more adverse financial outcomes compared with patients without diabetes, highlighting the need to consider patient financial health when treating type 2 diabetes, particularly for patient groups at higher risk.
2型糖尿病很常见,且与不良的财务状况相关。
调查2型糖尿病与不良财务后果之间的关联,并确定有风险的患者群体。
设计、设置和参与者:这项经济评估研究分析了2017年10月1日至2021年12月31日期间在俄亥俄州一家初级保健医疗中心至少有1次医疗就诊记录的18岁及以上成年人的电子健康记录与信用记录。如果患者健康记录中报告了糖化血红蛋白值、2型糖尿病诊断代码或抗糖尿病药物处方,则纳入研究。
2型糖尿病。
主要结局是任何不良财务后果、次级信用评分以下、催收中的非医疗和医疗债务、逾期债务、债务核销、破产申请和止赎的调整概率。调整因素包括年龄、性别、种族、西班牙裔、工资收入、健康保险类型、暴露期和季度指标。
研究人群包括166285名患者(平均[标准差]年龄为52.3[15.3]岁;55.0%为女性;0.2%为美洲印第安人或阿拉斯加原住民或夏威夷原住民或太平洋岛民,3.5%为亚洲人,19.1%为黑人,73.2%为白人;0.8%为多种族;2.1%为西班牙裔,97.9%为非西班牙裔),其中41.7%被诊断为2型糖尿病。在分析样本中,50.8%没有劳动收入,32.6%有医疗保险。患有糖尿病与未患糖尿病的患者相比,任何不良财务后果的估计概率显著更高(64.5%[95%置信区间,64.1%-64.9%]对49.9%[95%置信区间,49.6%-50.2%])、次级信用评分以下(59.7%[95%置信区间,59.3%-60.1%]对45.9%[95%置信区间,45.6%-46.2%])、医疗债务催收(36.9%[95%置信区间,36.5%-37.3%]对23.9%[95%置信区间,23.7%-24.2%])、非医疗债务催收(38.4%[95%置信区间,38.0%-38.8%]对27.7%[95%置信区间,27.5%-28.0%])、逾期债务(23.3%[95%置信区间,22.9%-23.7%]对15.6%[95%置信区间,15.4%-15.8%])、债务核销(15.4%[95%置信区间,15.1%-15.8%]对10.1%[95%置信区间,9.9%-10.2%])、破产申请(2.1%[95%置信区间,2.0%-2.3%]对1.4%[95%置信区间,1.3%-1.5%])和止赎(0.5%[95%置信区间,0.5%-0.6%]对0.3%[95%置信区间,0.2%-0.4%])。与未患糖尿病的患者相比,患有糖尿病的患者经历了更多的不良财务后果(1.9对1.2),且信用评分更低(平均[标准误],618.7[0.4]对664.2[0.5])。患有糖尿病与未患糖尿病的患者相比,催收中的非医疗债务最高金额更高(1875美元[95%置信区间,1834美元-1916美元]对1361美元[95%置信区间,1333美元-1389美元]),逾期债务也是如此(11387美元[95%置信区间,10796美元-11977美元]对7630美元[95%置信区间,7305美元-7955美元])。在黑人、参加医疗补助计划、西班牙裔、65岁以下、没有劳动收入和女性患者中,不良财务后果的调整患病率更高。
这项将患者健康记录与信用记录和工资收入相关联的经济评估表明,2型糖尿病与不良财务后果呈正相关。这些发现表明,与未患糖尿病的患者相比,2型糖尿病患者可能会经历更多的不良财务后果,这凸显了在治疗2型糖尿病时考虑患者财务健康的必要性,特别是对于风险较高的患者群体。